Neuromuscular diseases refer to a group of conditions that affect the nerves that communicate signals between the brain and the muscles. These diseases can result from a genetic disorder, an acquired disorder such as injury or infection, or a metabolic imbalance. Symptoms vary depending on the specific condition, but may include muscle weakness, pain, stiffness, spasms, fatigue, numbness, twitching or cramping. Neuromuscular diseases can have a dramatic impact on quality of life, and can cause disability or even loss of life. The most common neuromuscular diseases are the muscular dystrophies and myasthenia gravis. Muscular dystrophies is an umbrella term for a group of inherited disorders characterized by weakening and wasting of muscle tissue. Myasthenia gravis is an autoimmune disorder that causes weakness in the voluntary muscles, typically the arms and legs. Other neuromuscular diseases include ALS, Charcot-Marie-Tooth disease, peripheral neuropathy and many others. Diagnosing neuromuscular disease may involve imaging scans, nerve and muscle tests, electromyography and genetic tests. Treatment depends on the specific disorder and may include medications, physical therapy and surgery. For some diseases the only treatment available is supportive care, such as physical therapy, orthotics and assistive devices. When living with a neuromuscular disease, lifestyle modifications can help minimize symptoms, such as a balanced diet that promotes muscle strength and endurance, a regular exercise routine to maintain muscle function, and adequate rest to fight fatigue.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom